Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Invested Capital (2016 - 2026)

Collegium Pharmaceutical has reported Invested Capital over the past 11 years, most recently at $319.2 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 23.83% year-over-year to $319.2 million; the TTM value through Dec 2025 reached $319.2 million, up 23.83%, while the annual FY2025 figure was $319.2 million, 23.83% up from the prior year.
  • Invested Capital for Q4 2025 was $319.2 million at Collegium Pharmaceutical, down from $339.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $846.1 million in Q1 2022 and troughed at $257.8 million in Q4 2024.
  • A 5-year average of $434.9 million and a median of $369.2 million in 2021 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: skyrocketed 164.37% in 2022 and later tumbled 50.8% in 2023.
  • Year by year, Invested Capital stood at $315.4 million in 2021, then soared by 144.06% to $769.8 million in 2022, then tumbled by 50.8% to $378.8 million in 2023, then plummeted by 31.94% to $257.8 million in 2024, then grew by 23.83% to $319.2 million in 2025.
  • Business Quant data shows Invested Capital for COLL at $319.2 million in Q4 2025, $339.4 million in Q3 2025, and $296.8 million in Q2 2025.